Abstract

The present invention relates to a composition for treating, improving, or preventing Alzheimer's disease caused by ApoE4 gene mutation, the composition including Banha-Sasim-Tang as an active ingredient. The present invention relates to a composition for treating, improving, or preventing Alzheimer's disease caused by ApoE4 gene mutation, the composition including Banha-Sasim-Tang as an active ingredient. The composition including Banha-Sasim-Tang as an active ingredient of the present invention and a treatment method exhibit excellent effects of reducing amyloid beta proteins and inhibiting deposition thereof, which are specific to Alzheimer's disease caused by ApoE4 gene mutation, thereby having high applicability as a specific composition for preventing, improving, or treating Alzheimer's disease caused by ApoE4 gene mutation.

IPC Classes  ?

• A61K 36/258 - Panax (ginseng)
• A61K 36/484 - Glycyrrhiza (licorice)
• A61K 36/539 - Scutellaria (skullcap)
• A61K 36/718 - Coptis (goldthread)
• A61K 36/725 - Ziziphus, e.g. jujube
• A61K 36/8888 - Pinellia
• A61K 36/9068 - Zingiber, e.g. garden ginger
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to an anticancer use of aristoloxazine C, and more specifically to a pharmaceutical composition and a health functional food composition which use aristoloxazine C represented by Chemical Formula 1 or an isomer or pharmaceutically acceptable salt thereof, a method for preventing, ameliorating or treating cancer by using same; and a method for isolating aristoloxazine C.

IPC Classes  ?

• C07D 498/04 - Ortho-condensed systems
• A61K 31/536 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
• A61K 36/268 - Asarum (wild ginger)
• A61P 35/00 - Antineoplastic agents

Abstract

In a method for ameliorating or treating a respiratory disease, a composition including a Lysimachia mauritiana extract as effective component is administered to a subject in need thereof. Since the Lysimachia mauritiana extract is effective in reducing the production amount of the chemokine RANTES, an inflammatory mediator, from bronchial epithelial cells, which are respiratory cells, the composition can be advantageously used as a functional health food or medicine for respiratory diseases including asthma or chronic obstructive pulmonary disease (COPD).

IPC Classes  ?

• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present invention relates to a composition for preventing, alleviating, or treating atopic dermatitis, containing an extract of Scutellaria baicalensis and Raphanus sativus L. seeds as an active ingredient. Specifically, a Scutellaria baicalensis extract and a Raphanus sativus L. seed extract exhibit cytotoxicity or have no significant difference in NO production inhibitory effects, whereas the extract of Scutellaria baicalensis and Raphanus sativus L. seeds of the present invention, extracted after mixing at a weight ratio of 2-4:8-6, significantly inhibits LPS-induced NO production without cytotoxicity, reduces the thickness of atopic dermatitis-induced skin in an animal model, has a skin moisturizing effect, and significantly reduces the production of atopic dermatitis-related factors of IgE and IL-4, and thus the present invention can be usefully used in health functional foods, medicines and the like for preventing, alleviating, or treating atopic dermatitis.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/539 - Scutellaria (skullcap)
• A61K 36/31 - Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
• A61P 17/00 - Drugs for dermatological disorders
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

The present invention relates to a composition for inhibiting proliferation of tumor comprising Sanguisorba officinalis extract as effective component. Specifically, as the Sanguisorba officinalis extract binds to PD-L1 present on the surface of cancer cells, the interaction between cancer cells and PD-1 on the surface of T cells is blocked to activate T cells, and thus an inhibitory effect on tumor proliferation is exhibited. Furthermore, when administered to an animal model induced with colorectal cancer, it is possible to obtain a decrease in tumor size and tumor weight and also the enhanced secretion of immune cells (CD8 T cells) and granzyme B in cancer tissues.

IPC Classes  ?

• A61K 36/739 - Sanguisorba (burnet)
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a composition containing a plant extract of the genus Philadelphus as an active ingredient, for the prevention, alleviation, or treatment of tuberculosis. The plant extract of the genus Philadelphus significantly reduces the number of Mycobacterium tuberculosis in (in vivo samples of) mice as well as macrophages derived from mouse bone marrow infected with Mycobacterium tuberculosis, and exhibits synergistic effects on the reduction of Mycobacterium tuberculosis when co-administered with an antituberculosis agent, and thus the plant extract of the genus Philadelphus of present invention may be usefully employed as an antituberculosis agent.

IPC Classes  ?

• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/06 - Antibacterial agents for tuberculosis
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

Disclosed are a method and apparatus for assessing a cognitive function using brain waves. The method for assessing a cognitive function includes the steps of: measuring event-related potential (ERP) signals generated in each of the left and right prefrontal lobes of a user by using a tool for assessing a cognitive function; calculating a phase-locking value (PLV) between the ERP signals; and evaluating the cognitive function of the user by means of the PLV between the ERP signals.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/369 - Electroencephalography [EEG]
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The present invention relates to a composition for improving memory and preventing, alleviating or treating cognitive impairment, containing an Orixa japonica extract as an active ingredient. The Orixa japonica extract of the present invention has an excellent neuroprotective effect and, in particular, the neuroprotective effect of an Orixa japonica leaf extract is remarkably better than that of an Orixa japonica stem extract, and memory and cognitive function are improved by administering the Orixa japonica leaf extract to an animal model in scopolamine-induced cognitive decline, and thus the present invention can be effectively used as a health functional food for improving memory and cognitive function disorders and as a medicine and a feed additive for preventing, alleviating or treating degenerative brain diseases.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/758 - Zanthoxylum, e.g. pricklyash
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

A composition for preventing, ameliorating or treating a respiratory disease includes fermented Centella asiatica extract as effective component. The composition is effective in, in bronchial epithelial cells as respiratory cells, reducing the production amount of the inflammatory chemokine RANTES, protecting damaged cells induced by LPS, and reducing the expression level of the inflammatory cytokine IL-6, and it can also reduce the neutrophil count and regulate the expression level of inflammatory cytokines or chemokines in an animal model of lung injury. Accordingly, it can be advantageously used for a functional health food for preventing or ameliorating a respiratory disease, or a pharmaceutical product for preventing or treating a respiratory disease.

IPC Classes  ?

• A61K 36/23 - Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 36/06 - Fungi, e.g. yeasts
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

FNDC1, COL3A1, CX3CR1, SLC16A5, EPM2A, SLC35B3, PRTFDC1, CSRNP2, CCL16, HOXB4, GVINP1, LOC339874, MTRNR2L1LOC148709LOC148709, as an active ingredient.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol
• G01N 30/72 - Mass spectrometers

Abstract

The present invention relates to a blood circulation improvement composition containing a Capsicum annuum by-product extract as an active ingredient. A Capsicum annuum by-product, specifically, a Capsicum annuum leaf or Capsicum annuum branch extract, has an excellent platelet aggregation inhibitory effect and, in particular, the platelet aggregation inhibitory effect of an ethanol extract is superior to that of a water extract, and thus the composition of the present invention, containing a Capsicum annuum by-product extract as an active ingredient, can be effectively used as a component of a therapeutic agent for thrombosis, an antithrombotic health functional food, and an antithrombotic herbal composition.

IPC Classes  ?

• A61K 36/81 - Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

The present invention relates to a composition comprising a Dolichos lablab Linne extract as an active ingredient for the prevention, amelioration or treatment of allergic respiratory diseases. Specifically, in an allergic rhinitis-induced animal model, a Dolichos lablab Linne extract exhibited the effects of ameliorating symptoms of sneezing and nose scratching, reducing serum levels of IgE, histamine, and IL-13 increased by induced rhinitis, and inhibiting the infiltration of immune cells such as eosinophils, macrophages, and lymphocytes into nasal lavage fluid. Additionally, having excellent effects in inhibiting the production of Th2 cytokines and histamine, chikusetsusaponin IVa isolated from the Dolichos lablab Linne extract can be advantageously used in health functional foods and pharmaceuticals for allergic respiratory diseases including allergic rhinitis.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23P 10/00 - Shaping or working of foodstuffs characterised by the products
• A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
• A61P 11/02 - Nasal agents, e.g. decongestants
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

The present invention relates to a composition for the prevention, amelioration, or treatment of gastrointestinal diseases, comprising a Cucumis melo L. extract as an active ingredient, wherein the administration of the Cucumis melo L. extract significantly reduces a gastric lesion index due to gastric mucosal damage, reduces histamine content, which in gastric irritation or inflammatory conditions leads to high acid secretion and mucosal damage, decreases the gene expression of inflammatory cytokines in the gastric mucosa, and also increases the gene expression of proteins with antioxidant effects and proteins with gastro-protective functions in the gastric mucosa, and therefore the present invention may be useful as a medicine, health functional food, or feed additive for gastrointestinal diseases caused by gastric mucosal damage.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23P 10/00 - Shaping or working of foodstuffs characterised by the products
• A23L 19/00 - Products from fruits or vegetablesPreparation or treatment thereof
• A61K 36/42 - Cucurbitaceae (Cucumber family)
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

The present invention relates to a tongue image capturing system that can capture frontal and lateral images of the tongue by using a smartphone or a web camera as a frontal camera and a lateral camera, and analyze the images, thereby enabling the diagnose of the tongue without implementing a separate complex device as a tongue diagnosis device.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing

Abstract

A composition for inhibiting proliferation of tumor comprising Rubus coreanus extract as effective component. It was found that the Rubus coreanus extract binds to PD-L1 present on the surface of cancer cells, thus blocking the interaction between cancer cells and PD-1 on the surface of T cells to activate T cells and exhibit an inhibitory effect on tumor proliferation, and it was also found that the Rubus coreanus extract shows an excellent anti-tumor immune activity in humanized PD-1 animal model induced with MC38 colorectal cancer expressing human PD-L1 and also a synergistic effect when co-administered with anti-cancer agents.

IPC Classes  ?

• A61K 36/73 - Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The present invention relates to a composition for preventing, ameliorating, or treating cognitive dysfunction, containing a dopamine production inhibitor or a dopamine receptor antagonist and, more specifically, provides a composition for preventing, ameliorating, or treating cognitive dysfunction, a composition for improving learning ability or memory, and/or a composition for ameliorating cognitive decline, which can improve cognitive ability, short-term memory, spatial working memory, learning ability, etc. by inhibiting dopamine production or blocking dopamine receptors. In addition, provided is a method of screening for substances effective in preventing, ameliorating, or treating cognitive dysfunction, improving learning ability and memory, and ameliorating cognitive decline, by screening for substances that inhibit dopamine production in animal models in which cognitive dysfunction or cognitive decline is induced due to increased dopamine levels, or in skin cells in which dopamine secretion is increased.

IPC Classes  ?

• A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61Q 19/00 - Preparations for care of the skin
• A01K 67/00 - Rearing or breeding animals, not otherwise provided forNew or modified breeds of animals
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to a composition for preventing or treating cognitive dysfunction or memory impairment related diseases, including an extract of Ligustrum foliosum Nakai. The extract of Ligustrum foliosum Nakai of the present invention exhibits nerve cell protection, apoptosis-inhibitory effects, and cognitive function improvement effects, and thus can be useful as a therapeutic agent for cognitive dysfunction or memory impairment related diseases.

IPC Classes  ?

• A61K 36/638 - Ligustrum, e.g. Chinese privet
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

OOOOOOOO-glucoside represented by formula 2 below.

IPC Classes  ?

• C07H 17/07 - Benzo[b]pyran-4-ones
• C07H 1/08 - SeparationPurification from natural products
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61P 35/00 - Antineoplastic agents
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives

Abstract

The present invention relates to an immunoenhancing composition that contains colored rice extract as an active ingredient. Specifically, the colored rice extract of the present invention, which is prepared from colored rice obtained from a mutant rice plant (KCTC 18500P) capable of producing seeds with a yellow bran layer, has the excellent effect of proliferating macrophages and thus can be advantageously utilized in health functional food compositions for enhancing immunity, animal feed additives for boosting immunity, or pharmaceutical compositions for the prevention and treatment of diseases caused by immune deficiency.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/899 - Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 17/00 - Drugs for dermatological disorders
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

The present invention relates to a composition including a colored rice extract as an active ingredient for the prevention, reduction, or treatment of skin wrinkles. Specifically, the colored rice extract of the present invention, which is derived from a mutant rice plant (KCTC 18500P) capable of producing seeds with a yellow bran layer, has the effect of reducing the expression of MMP-9 (matrix metalloproteinase-9) and thus can be utilized in cosmetics, health functional foods, or pharmaceuticals for the prevention, reduction, or treatment of skin wrinkles.

IPC Classes  ?

• A61K 8/9794 - Liliopsida [monocotyledons]
• A61Q 19/08 - Anti-ageing preparations
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/899 - Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
• A61P 17/00 - Drugs for dermatological disorders
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

The present invention relates to a composition for preventing, ameliorating, or treating obesity, comprising colored rice extract as an active ingredient. Specifically, as the colored rice extract of the present invention obtained from a mutant rice plant (KCTC 18500P) capable of producing seeds with a yellow seed coat, has the effect of inhibiting fat accumulation in the 3T3-L1 cell line and suppressing the expression of obesity-related genes (PPARγ, and FASN), the colored rice extract may be very effectively used in functional health foods or pharmaceuticals for preventing, ameliorating, or treating obesity.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A01H 6/46 - Gramineae or Poaceae, e.g. ryegrass, rice, wheat or maize
• A61K 36/899 - Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
• A61P 3/04 - AnorexiantsAntiobesity agents
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

The present invention relates to a composition for preventing, ameliorating, or treating Alzheimer's disease, comprising, as active ingredients, a Vitis vinifera stem extract and a compound isolated therefrom. The active ingredient of the present invention, the Vitis vinifera stem extract or vitisin A, may inhibit infection caused by herpes simplex virus and have an excellent inhibitory effect on Alzheimer's disease triggers in the brain tissue of an animal model infected with herpes simplex virus, and thus the composition of the present invention can be useful as a therapeutic agent for Alzheimer's disease, a health functional food or feed additive for preventing or ameliorating Alzheimer's disease.

IPC Classes  ?

• A61K 36/87 - Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms
• A23K 20/121 - Heterocyclic compounds containing oxygen or sulfur as hetero atom

Abstract

The present invention pertains to: an antiviral composition against coronavirus, containing a maple leaf extract as an active ingredient; a method for preventing or treating coronavirus infection diseases, the method comprising the step of administering a composition containing a maple leaf extract as an active ingredient to an individual who shows symptoms of coronavirus infection or is at risk of developing such symptoms; and a use of a composition containing a maple leaf extract as an active ingredient for antiviral activity against coronavirus. The present invention can be utilized in the development of antiviral agents for preventing or treating coronavirus diseases.

IPC Classes  ?

• A61K 36/20 - Aceraceae (Maple family)
• A61K 36/538 - Schizonepeta
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 36/14 - Cupressaceae (Cypress family), e.g. juniper or cypress
• A61K 36/296 - Epimedium
• A61K 36/72 - Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
• A61P 31/14 - Antivirals for RNA viruses
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

A cognitive training method based on eye tracking according to the present invention may comprise the steps of: providing content including a target stimulus and a distractor stimulus to a virtual space of each of a plurality of participants; monitoring the eye of each of the plurality of participants with respect to the target stimulus and the distractor stimulus on the basis of an eye tracking method; on the basis of a result of the monitoring, calculating a concentration level for the content for each of the plurality of participants; and providing a graphic object classified for each of the plurality of participants to a virtual space of an instructor, and providing information on the concentration level of each of the plurality of participants to the graphic object.

IPC Classes  ?

• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• G09B 5/12 - Electrically-operated educational appliances providing for individual presentation of information to a plurality of student stations different stations being capable of presenting different information simultaneously

Abstract

The present invention relates to a composition for the prevention, amelioration or treatment of an anterior segment eye disease, the composition comprising a plant extract of the genus Aloe as an active ingredient. When the Aloe vera extract of the present invention is orally administered to a dry eye-induced animal model, there are the effects of increasing tear volume and reducing corneal distortion and corneal smoothness score, and thus, the Aloe vera extract can be effectively used in health functional foods or medicines for anterior segment eye diseases.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 3/44 - Freeze-drying
• A23L 29/00 - Foods or foodstuffs containing additivesPreparation or treatment thereof
• A61K 36/886 - Aloeaceae (Aloe family), e.g. aloe vera
• A61P 27/02 - Ophthalmic agents
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to a composition for the prevention, amelioration or treatment of fatty liver disease, containing a Glycine max extract as an active ingredient. The Glycine max extract of the present invention, particularly a Glycine max extract having a genetic resource name of Shinpaldalkong ( IT No.: IT343931) or KLG 16001 (IT No.: IT238318) has the effects of suppressing fatty liver formation and reducing blood ALT and AST contents that are increased by a high-sucrose diet, in a high-sucrose diet animal model, and thus can be effectively used as a therapeutic agent for fatty liver disease or an ingredient of a health functional food for ameliorating fatty liver.

IPC Classes  ?

• A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

A composition for strengthening, developing, differentiating, or regenerating muscle, or preventing, ameliorating, or treating muscle loss or muscle fatigue includes a Schizonepeta tenuifolia extract as an effective component. The Schizonepeta tenuifolia extract as an effective component has the effects of restoring the viability of muscle cells, increasing the endurance time on the rotarod performance test, i.e., the holding time without falling off from the rod, compared to the control group, reducing the content of LDH, AST, and ALT in blood, increasing the grip strength, enhancing the expression amount of energy metabolism-related genes in muscle tissues, increasing the density of muscle fibers in muscle tissues, inducing a change in the fibroblast arrangement to have a well-organized structure, and reducing the expression of MuRF1 in muscle tissues, as compared to the control group.

IPC Classes  ?

• A61K 36/538 - Schizonepeta
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The present invention relates to a composition for prevention, alleviation, or treatment of bone disease, containing salvianolic acid as an active ingredient, the salvianolic acid of the present invention, specifically, salvianolic acid A or methyl salvionolate A having an excellent effect of promoting osteoblast differentiation, methyl salvionolate A having an excellent effect of inhibiting osteoclast differentiation, and salvianolic acid A, when administered in an ovariectomized mouse, having an excellent effect of inhibiting bone loss, and thus the composition of the present invention, containing salvianolic acid A or methyl salvionolate A as an active ingredient may be usefully employed as an agent for prevention, alleviation, or treatment of bone disease.

IPC Classes  ?

• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61P 19/00 - Drugs for skeletal disorders
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A23K 20/111 - Aromatic compounds

Abstract

A composition for preventing, ameliorating or treating an androgen-dependent disorder includes Phyllostachys pubescens extract as an effective component. It was found that, compared to the extracts of other types of bamboo, the Phyllostachys pubescens extract of the present invention can significantly reduce the expression amount of the SRD5A2 gene which encodes 5α-reductase while hardly showing any cytotoxicity. The composition of the present invention was found to have effects that can reduce the prostate weight, reduce the proliferation of epithelial cells in prostate tissues, and also can reduce the content of testosterone, dihydrotestosterone, PSA, and SRD5A2 in blood serum. Thus, the composition of the present invention can be advantageously used for an androgen-dependent disorder.

IPC Classes  ?

• A61K 36/899 - Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
• A61P 5/26 - Androgens
• A61K 8/9794 - Liliopsida [monocotyledons]

Abstract

The present invention relates to a composition for the prevention, amelioration or treatment of rhinitis, the composition comprising a Gardenia jasminoides extract from which a pigment is removed, as an active ingredient. The Gardenia jasminoides extract, from which a pigment is removed, showed a reduced number of sneezes and a reduced number of nose rubbings in a rhinitis-induced animal model, and has the effect of reducing inflammation in nasal tissue, and thus can be used as a health functional food, medicine or quasi-drug for the prevention, amelioration or treatment of rhinitis.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 5/20 - Removal of unwanted matter, e.g. deodorisation or detoxification
• A61K 36/744 - Gardenia
• A61P 11/02 - Nasal agents, e.g. decongestants

Abstract

The present invention relates to a composition for promoting memory and preventing, alleviating or treating cognitive impairment, containing Yuk-Gunja-Tang as an active ingredient. Specifically, Yuk-Gunja-Tang, which is prepared by putting a mixture of Panax ginseng, Atractylodis Rhizoma Alba, Poria cocos, Glycyrrhizae Radix et Rhizoma, Citri Unshius Pericarpium, Pinellia ternata, Zingiberis Rhizoma Recens and Zizyphi Fructus in water and boiling same, has neuroprotective effects superior to those of individual extracts of each of Panax ginseng, Atractylodis rhizoma alba, Poria cocos, Glycyrrhizae Radix et Rhizoma, Citri Unshius Pericarpium, Pinellia ternata, Zingiberis Rhizoma Recens and Zizyphi Fructus, and exhibits effects of improving memory and cognitive function when administered to an animal model with scopolamine-induced cognitive decline, and thus can be effectively used as a food, a drug and the like for prevention or treatment of brain diseases including Alzheimer's disease, Parkinson's disease, mild cognitive impairment and the like.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms
• A61K 36/258 - Panax (ginseng)
• A61K 36/284 - Atractylodes
• A61K 36/076 - Poria
• A61K 36/484 - Glycyrrhiza (licorice)
• A61K 36/752 - Citrus, e.g. lime, orange or lemon
• A61K 36/8888 - Pinellia
• A61K 36/9068 - Zingiber, e.g. garden ginger
• A61K 36/725 - Ziziphus, e.g. jujube

Abstract

The present invention relates to a composition for prevention, amelioration or treatment of a coronavirus infection, comprising a Sorbus commixta extract as an active ingredient. The Sorbus commixta extract has the effect of protecting cells from a coronavirus infection and has an excellent effect of inhibiting viral replication in cells and viral infection in cells, and thus the composition of the present invention, comprising the Sorbus commixta extract as an active ingredient may be usefully employed as a coronavirus infection therapeutic agent, an anti-coronavirus health functional food, quasi-drug, cosmetic or feed additive.

IPC Classes  ?

• A61K 36/73 - Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
• A61P 31/14 - Antivirals for RNA viruses
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61Q 19/00 - Preparations for care of the skin
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

The present invention relates to a composition for the prevention, amelioration or treatment of coronavirus infection, the composition comprising a Siegesbeckia pubescens extract as an active ingredient. The Siegesbeckia pubescens extract has the effect of protecting cells from coronavirus infection, and has an excellent effect of suppressing viral replication in cells and viral infection in cells, and thus, the composition comprising the Siegesbeckia pubescens extract as an active ingredient according to the present invention can be effectively used as a therapeutic agent for coronavirus infection or as an anti-coronavirus health functional food, quasi-drug, cosmetic, or feed additive.

IPC Classes  ?

• A61K 36/28 - Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
• A61P 31/14 - Antivirals for RNA viruses
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61Q 19/00 - Preparations for care of the skin
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

The present invention relates to a composition including a Daihong Crataegus pinnatifida Bunge extract as an active ingredient for improving gut health or treating inflammatory bowel disease. The Daihong Crataegus pinnatifida Bunge extract is almost free of cytotoxicity, exhibits protective activity for the intestines, reduces the expression levels of necroptosis markers, and has the effect of restoring the length of the intestines in animal models with induced inflammatory bowel disease. Therefore, the extract can be beneficially used in health functional foods or pharmaceuticals for intestinal health.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/734 - Crataegus (hawthorn)
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms
• A23P 10/00 - Shaping or working of foodstuffs characterised by the products

Abstract

22, and LTB4) and cartilage degeneration-inducing factors (MMP-2 and MMP). Therefore, the composition of the present invention can be effectively used for preventing, ameliorating, or treating arthritis and joint pain.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

The present invention relates to a composition for the prevention, amelioration or treatment of allergic respiratory diseases comprising an Alpinia officinarum Hance extract as an active ingredient. Specifically, as an Alpinia officinarum Hance extract has excellent effects of reducing airway hyperresponsiveness, inhibiting the infiltration of immune cells such as eosinophils and neutrophils increased by asthma induction in a nasal lavage fluid, reducing IgE content in serum, and selectively inhibiting the Th2 immune response, the Alpinia officinarum Hance extract can be effectively used in functional health foods, medicines, etc. for allergic respiratory diseases.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/9062 - Alpinia, e.g. red ginger or galangal
• A61P 37/08 - Antiallergic agents
• A61P 11/00 - Drugs for disorders of the respiratory system
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

The present invention relates to a composition for preventing, ameliorating, or treating coronavirus infections, the composition comprising Euljatang extract as an active ingredient. The Euljatang extract has excellent effects of protecting cells from coronavirus infections, inhibiting the proliferation of viruses, and reducing the lethality of infections in animal models infected with coronaviruses, and thus the composition according to the present invention comprising the Euljatang extract as an active ingredient can be effectively used as a therapeutic agent for coronavirus infections, health functional food for anti-coronavirus, a quasi-drug, a cosmetic, or a feed additive.

IPC Classes  ?

• A61K 36/232 - Angelica
• A61K 36/233 - Bupleurum
• A61K 36/53 - Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
• A61K 36/484 - Glycyrrhiza (licorice)
• A61K 36/71 - Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
• A61K 36/70 - Polygonaceae (Buckwheat family), e.g. spineflower or dock
• A61P 31/14 - Antivirals for RNA viruses
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61Q 19/00 - Preparations for care of the skin

Abstract

The present invention relates to a composition for preventing, alleviating or treating coronavirus infection, containing a Gwakhyanggunggi-san extract as an active ingredient. The Gwakhyangjeonggi-san extract has the excellent effects of protecting cells from coronavirus infection, inhibiting the proliferation of viruses and reducing the mortality rate caused by infection in animal models infected with coronavirus, and thus the composition of the present invention, comprising the Gwakhyangjeonggi-san extract as an active ingredient, can be effectively used as an agent for treating coronavirus infection, an anti-coronavirus health functional food, quasi-drug, cosmetic product, or feed additive.

IPC Classes  ?

• A61K 36/532 - Agastache, e.g. giant hyssop
• A61K 36/535 - Perilla (beefsteak plant)
• A61K 36/232 - Angelica
• A61K 36/889 - Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
• A61K 36/076 - Poria
• A61K 36/54 - Lauraceae (Laurel family), e.g. cinnamon or sassafras
• A61K 36/284 - Atractylodes
• A61K 36/752 - Citrus, e.g. lime, orange or lemon
• A61K 36/8888 - Pinellia
• A61K 36/346 - Platycodon

Abstract

The present invention relates to a composition for preventing, ameliorating, or treating atopic dermatitis comprising an extract of Alpinia officinarum Hance as an active ingredient. Specifically, as an extract of Alpinia officinarum Hance suppresses an increase in ear thickness in an animal model with atopic dermatitis, ameliorates skin lesions such as skin damage and the like, and has an excellent effect in reducing the secretion of chemokine and immunoglobulin E, the extract of Alpinia officinarum Hance can be effectively used in functional health foods, pharmaceutical products, etc. for atopic dermatitis.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/9062 - Alpinia, e.g. red ginger or galangal
• A61P 17/00 - Drugs for dermatological disorders
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

The present invention relates to a method for segmenting the abdomen for abdominal measurement and stimulation. Designed to uniformly divide the abdomen on the basis of location, the method allows for diagnostic and therapeutic actions to be taken in each segment and thus assists acupuncturists and medical professionals in abdominal diagnosis.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges

Abstract

The present invention relates to: an antiviral pharmaceutical composition containing a maple extract as an active ingredient; a pharmaceutical composition, containing a maple extract as an active ingredient, for preventing or treating influenza virus infectious diseases; a method for preventing or treating influenza virus infectious diseases, the method comprising a step for administering a composition containing a maple extract as an active ingredient to an individual who shows or is likely to show symptoms of influenza virus infectious diseases; and an antiviral use of the composition containing a maple extract as an active ingredient. A maple leaf extract exhibits the effect of inhibiting influenza virus infection, and thus can be used for developing an antiviral agent for preventing or treating influenza virus infectious diseases.

IPC Classes  ?

• A61K 36/20 - Aceraceae (Maple family)
• A61P 31/12 - Antivirals
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

The present invention relates to a composition for the prevention, amelioration or treatment of coronavirus infection, comprising a Melia toosendan fructus extract as an active ingredient. The Melia toosendan fructus extract has the effect of protecting cells from coronavirus infection, and has an excellent effect of suppressing viral replication in cells and viral infection in cells, and thus, the composition of the present invention, comprising the Melia toosendan fructus extract as an active ingredient, can be effectively used as a therapeutic agent for coronavirus infection or a health functional food, quasi-drug, cosmetic or feed additive for anti-coronavirus.

IPC Classes  ?

• A61K 36/58 - Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
• A61P 31/14 - Antivirals for RNA viruses
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61Q 19/00 - Preparations for care of the skin
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

The present invention relates to a composition for the prevention, amelioration or treatment of asthma, containing a Malus baccata var. mandshurica extract as an active ingredient. The Malus baccata var. mandshurica extract, which is an active ingredient of the present invention, has the effects of reducing the number of inflammatory cells in an asthma animal model, reducing IgE content in the bronchoalveolar lavage fluid (BALF) and plasma of an asthma animal model, reducing IL-13 content in the BALF of an asthma animal model, reducing the hyperplasia of mucus-secreting cells due to infiltration of inflammatory cells into lung tissue or bronchial remodeling and the amount of mucus, and reducing the activity of β-hexosaminidase in mast cells with induced degranulation, and thus can be effectively used as a therapeutic agent for asthma and a material of a health functional food for ameliorating asthma.

IPC Classes  ?

• A61K 36/73 - Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
• A61P 11/06 - Antiasthmatics
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

The present invention relates to a composition for hangover relief, the composition comprising a Cucumis melo L. extract as an active ingredient. Specifically, the Cucumis melo L. extract can mitigate an increase in blood ethanol concentration caused by alcohol consumption and effectively increase the activity of ADH and ALDH in the blood. Thus, the composition according to the present invention can be effectively used as a health-functional food, drug, or quasi-drug for hangover relief.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23P 10/20 - AgglomeratingGranulatingTabletting
• A23P 10/28 - TablettingMaking food bars by compression of a dry powdered mixture
• A23P 10/30 - Encapsulation of particles, e.g. foodstuff additives
• A23L 2/38 - Other non-alcoholic beverages
• A61K 36/42 - Cucurbitaceae (Cucumber family)
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

The present invention relates to a screening composition for a therapeutic agent for coronavirus infection, comprising a CoV RdRp expression vector and a bicistronic reporter vector, a screening kit for a therapeutic agent for coronavirus infection, comprising the composition, and a method for screening a therapeutic agent for coronavirus infection using the composition or kit. When the screening composition for a therapeutic agent for coronavirus infection, provided by the present invention, is used, candidate materials that can have direct influences on the activity of CoV RdRp can be screened more quickly and easily, and thus, the composition can be widely used in the development of therapeutic agents for coronavirus infection.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

The present invention relates to a composition which is for preventing, ameliorating, or treating metabolic diseases, and contains an extract of Lysimachia mauritiana as an active ingredient. The extract of Lysimachia mauritiana not only reduces body weight, weight gain, food efficiency ratio, body fat, fat cell size, liver weight, liver fat accumulation, blood triglycerides, total cholesterol, and LDL cholesterol and improves GPT, but also has the effect of inhibiting adipocyte differentiation and fat accumulation in 3T3-L1 adipocytes, and thus can be effectively used as a health functional food or medicine for preventing, ameliorating, or treating metabolic diseases including obesity, dyslipidemia, and fatty liver.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/06 - Antihyperlipidemics
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present invention relates to novel asaroidoxazine C and an anti-cancer use thereof. More specifically, provided are: asaroidoxazine C represented by Formula 1 below, an isomer thereof, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition and a functional health food composition using same; a method for preventing, ameliorating, or treating a cancer using same; and a method for isolating the asaroidoxazine C.

IPC Classes  ?

• C07D 498/04 - Ortho-condensed systems
• A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 36/268 - Asarum (wild ginger)
• A61P 35/00 - Antineoplastic agents
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives

Abstract

The present invention relates to an anticancer use of aristoloxazine C and, more specifically, to a pharmaceutical composition and a health functional food composition which use aristoloxazine C represented by chemical formula 1 or an isomer or pharmaceutically acceptable salt thereof, a method for preventing, ameliorating, or treating cancer by using same, and a method for isolating aristoloxazine C.

IPC Classes  ?

• A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 36/268 - Asarum (wild ginger)
• A61P 35/00 - Antineoplastic agents
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• C07D 498/04 - Ortho-condensed systems

Abstract

The present invention relates to a use of Asaroidoxazine B having anticancer activity and, more specifically, to: a pharmaceutical composition and a health functional food composition, each utilizing Asaroidoxazine B represented by chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt thereof; a method for preventing, alleviating, or treating cancer, using same; and a method for isolation of the Asaroidoxazine B.

IPC Classes  ?

• A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 36/268 - Asarum (wild ginger)
• A61P 35/00 - Antineoplastic agents
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• C07D 498/04 - Ortho-condensed systems

Abstract

The present invention relates to a composition for the prevention, amelioration or treatment of a respiratory disease, containing a Lysimachia mauritiana extract as an active ingredient. The Lysimachia mauritiana extract has the effect of reducing the amount of production of chemokine RANTES, which is a pro-inflammatory mediator, from bronchial epithelial cells, which are respiratory cells, and thus can be effectively used as a health functional food or medicine for a respiratory disease, including asthma or chronic obstructive pulmonary disease (COPD).

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present invention relates to a composition comprising a Cardamine flexuosa extract as an active ingredient for prevention, alleviation, or treatment of respiratory disease. The Cardamine flexuosa extract has the effect of reducing the production of chemokine RANTEST, which is an inflammation-inducing mediator, from bronchial epithelial cells, which are respiratory cells, and thus can be advantageously used as a health functional food, a medical product, or a feed additive against respiratory diseases including asthma or chronic obstructive pulmonary disease (COPD).

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/31 - Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present invention relates to a use of an Apios americana tuber extract for protection against alcoholic liver damage or alcoholic brain damage, and more particularly, provides a composition for protection against alcoholic liver damage or alcoholic brain damage and a method for protection against alcoholic liver damage or alcoholic brain damage, each using an Apios americana tuber extract. In addition, the present invention provides a composition for the prevention, alleviation, or treatment of alcoholic liver disease or brain nervous system disease and a method for the prevention, alleviation, or treatment of alcoholic liver disease or brain nervous system disease, each using an Apios americana tuber extract. Furthermore, the present invention provides a composition for relieving hangover and a method for relieving hangover, each using an Apios americana tuber extract.

IPC Classes  ?

• A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61P 25/00 - Drugs for disorders of the nervous system
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives

Abstract

The present invention relates to a 2-aminoquinazoline derivative or a pharmaceutically acceptable salt thereof and, more specifically, to a compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof, and an anti-viral pharmaceutical composition comprising same as an active ingredient. [chemical formula 1]

IPC Classes  ?

• C07D 239/95 - QuinazolinesHydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07F 9/06 - Phosphorus compounds without P—C bonds
• C07F 9/11 - Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to use of a composition comprising Banhasasim-tang as an active ingredient for the treatment, amelioration or prevention of Alzheimer's disease caused by ApoE4 genetic variation. The composition comprising Banhasasim-tang as an active ingredient and a treatment method, according to the present invention, exhibit excellent effects of reducing amyloid beta protein and inhibiting the precipitation thereof in a manner specific to Alzheimer's disease caused by ApoE4 genetic variation, and thus are greatly used as a preventive, ameliorating or therapeutic composition specific to Alzheimer's disease caused by ApoE4 genetic variation.

IPC Classes  ?

• A61K 36/8888 - Pinellia
• A61K 36/725 - Ziziphus, e.g. jujube
• A61K 36/484 - Glycyrrhiza (licorice)
• A61K 36/258 - Panax (ginseng)
• A61K 36/9068 - Zingiber, e.g. garden ginger
• A61K 36/53 - Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
• A61K 36/718 - Coptis (goldthread)
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives

Abstract

The present invention has confirmed that Castanea crenata Sieb reduces the expression of an influenza A virus protein, the expression of inflammatory cytokines increased by infection therewith, and the activity of NF-kB, remarkably reduces the mortality of an animal model infected with influenza A virus, suppresses weight loss caused by viral infection, and has the effect of inducing the expression of innate immunity-related factors and the phosphorylation of factors involved in the activation of immune-related signaling pathways. Therefore, Castanea crenata Sieb can have various useful applications for the prevention, alleviation or treatment of diseases caused by influenza A virus, and can have various useful applications for enhancing immune function.

IPC Classes  ?

• A61K 36/49 - Fagaceae (Beech family), e.g. oak or chestnut
• A61K 35/644 - BeeswaxPropolisRoyal jellyHoney
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms
• A23K 10/20 - Animal feeding-stuffs from material of animal origin
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives

Abstract

The present invention relates to a composition comprising a Rubus coreanus extract as an active ingredient for inhibiting tumor growth. The Rubus coreanus extract was identified to: bind to PD-L1 located on the surface of cancer cells to interfere with the interaction of cancer cells with PD-1 located on the surface of T cells and activate T cells, thereby exhibiting an inhibitory effect on tumor growth; have excellent anti-tumor immune efficacy in a humanized PD-1 animal model which expressed human PD-L1 and had MC38 colon cancer induced therein; and exhibit a synergistic effect when administered in combination with an anticancer agent.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/73 - Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• A23L 19/00 - Products from fruits or vegetablesPreparation or treatment thereof

Abstract

The present invention relates to a composition for the prevention, amelioration or treatment of muscle diseases, comprising ginsenoside Rc. Ginsenoside Rc inhibits myoblast apoptosis under oxidative stress, increases the activity of PGC1-α, which is a metabolic regulator and a mitochondrial biogenesis factor, in myoblasts and myotubes, inhibits a reduction in PGC1-α and MyH in myotubes, maintains mitochondrial mass, and suppresses muscle damage caused by oxidative stress by inhibiting an increase in MuRF and MAFbx, which are proteins involved in muscle cell breakdown, and thus can be used for the prevention, amelioration or treatment of muscle diseases, in particular, muscle diseases caused by decreased muscular function, muscle wasting, or muscular degeneration.

IPC Classes  ?

• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates

Abstract

A method and a device for improving deep learning performance for similar image classification are disclosed. A method for improving deep learning performance for similar image classification, according to one embodiment of the present invention, may comprise the steps of: creating a confusion matrix (CM) by using a correct answer value of label data and a prediction value of a model, generated during learning by means of a deep learning model with respect to an input image; defining, from the CM, a confusion rate (CR), which is the rate with respect to the difference between a class according to the prediction value and a class according to the correct answer value; and weighting the CR against a prescribed loss function so as to correct the learning process by means of the deep learning model.

IPC Classes  ?

• G06N 3/08 - Learning methods
• G06N 3/04 - Architecture, e.g. interconnection topology
• G06K 9/62 - Methods or arrangements for recognition using electronic means

Abstract

The present invention relates to a composition for preventing, alleviating, or treating respiratory diseases, comprising fermented centella asiatica extract as an active ingredient. The active ingredient of the present invention reduces the production of RANTES, which is an inflammatory chemokine, in bronchial epithelial cells, which are respiratory cells, has an effect of protecting cells damaged by LPS induction, and has an effect of reducing an expression level of inflammatory cytokine IL-6. In addition, the active ingredient can reduce the number of neutrophils and regulate the expression level of inflammatory cytokines or chemokines in lung injury animal models. As such, the active ingredient can be effectively used as: a health functional food for preventing or alleviating respiratory diseases; and a medicine for preventing or treating respiratory diseases.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A23L 33/14 - Yeasts or derivatives thereof
• A23L 3/00 - Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
• A61K 36/23 - Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

Provided are a vaccine adjuvant composition including, as an active ingredient, bavachin capable of improving antibody titer and enhancing cellular immunity and humoral immunity when administered together with an antigen, a vaccine preparation including the bavachin and an antigen, a method of promoting an immune response, the method including the step of administering the vaccine adjuvant composition to a subject together with a vaccine composition or before and after administration of the vaccine composition, and a vaccine adjuvant composition for promoting an immune response, the vaccine adjuvant composition including the bavachin. Since the vaccine adjuvant composition of the present invention includes bavachin isolated from an extract of Psoralea corylifolia, of which safety has been secured, it may exhibit safety and may enhance both the humoral and cellular immune responses as well as the titer of antibodies generated by antigens.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 37/04 - Immunostimulants

Abstract

A composition according to an embodiment of the present disclosure can be used for inhibiting tumor proliferation and includes a Salvia plebeia extract as an effective component. It was found that, as a result of binding to PD-L1 present on a surface of cancer cell, Salvia plebeia extract blocks the interaction between cancer cell and PD-1 present on a surface of immune T cell to activate T cells and exhibit an inhibitory effect on tumor proliferation. It was also found that, according to co-culture of cells of colon cancer, breast cancer, or lung cancer with T cells, the group treated with Salvia plebeia extract shows higher effect of causing cancer cell death.

IPC Classes  ?

• A61K 36/537 - Salvia (sage)
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The objective of the present invention is to provide an apparatus and method for evaluating meridian muscle activity, wherein the activity of each of a plurality of meridian muscle groups is evaluated using measurement data measured using a sensor and a simulation model. More specifically, the present invention comprises: a measurement unit for measuring the gait of a user; a calculation unit for calculating lower extremity joint torque values of the user using measurement results of the measurement unit; and an evaluation unit for evaluating the activity for each of the meridian muscles of the lower extremities of the user on the basis of the lower extremity joint torque values. According to the invention, a user's asymmetrical gait can be detected using only an apparatus having a simple structure.

IPC Classes  ?

• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/103 - Measuring devices for testing the shape, pattern, size or movement of the body or parts thereof, for diagnostic purposes
• A61B 5/397 - Analysis of electromyograms
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The present invention relates to a composition for inhibiting tumor growth, containing an extract of Sanguisorba officinalis as an active ingredient. It has been identified that a Sanguisorba officinalis extract binds to PD-L1 on cancer cell surfaces to block the interaction of cancer cells with PD-1 on the surface of T cells, and thus activates T cells to exhibit the effect of inhibiting tumor growth, and the present invention can reduce the size and weight of a tumor by being administered to an animal model in which colon cancer has been induced, and can increase immune cells (CD8 T cells) and granzyme B secretion in cancer tissues.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/739 - Sanguisorba (burnet)
• A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Lysimachiae HerbaRaphani SemenBuddlejae FlosBuddlejae Flos extract. The Lysimachiae Herba, Raphani Semen or Buddlejae Flos extract according to the present invention has the effect of fundamentally alleviating the symptoms of cancer cachexia by suppressing the loss of body weight, muscle and fat, caused by tumors, not due to an increase in feed intake through increased appetite, and is safe and has no side effects, and thus can be used for the prevention, amelioration or treatment of cachexia.

IPC Classes  ?

• A61K 36/56 - Loganiaceae (Logania family), e.g. trumpetflower or pinkroot
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61P 35/00 - Antineoplastic agents
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/31 - Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
• A61K 36/53 - Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender

Abstract

The Agastache rugosa extract or the isoagastachoside or crude polysaccharide fraction included in the extract according to the present invention can be prepared based on plants being domestically cultivated, and thus is advantageous in terms of time and cost, and can effectively inhibit the differentiation, growth, and bone resorption functions of osteoclast progenitor cells, thus increasing bone density and the like, and accordingly, can be effectively used for the prevention, amelioration, or treatment of diseases related to bone loss caused by differentiation into osteoclasts or excessive activity of osteoclasts. In addition, the active ingredient, which is a plant-derived natural substance, is safe due to fewer side effects on the human body compared to chemical drugs, and inhibits osteoclast progenitor cells independently of estrogen, and thus can be widely used in osteoporosis occurring due to various causes other than menopause.

IPC Classes  ?

• A61K 36/532 - Agastache, e.g. giant hyssop
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Abstract

The present invention relates to a composition for preventing, ameliorating, or treating muscle strengthening, muscle building, muscle differentiation, muscle regeneration, muscle loss, or muscle fatigue, comprising a Schizonepeta tenuifolia extract as an active ingredient. The Schizonepeta tenuifolia extract which is the active ingredient of the present invention has the effects of recovering cell viability of muscle cells, increasing the holding time without detachment from a rod as compared with a control group when a rotarod test is performed, and reducing amounts of LDH, AST, and ALT in the blood. In addition, the Schizonepeta tenuifolia extract has the effects of increasing grasping strength, increasing an expression level of an energy metabolism-related gene in muscle tissue, increasing the density of muscle fibers in muscle tissue, changing a fibroblast arrangement in an orderly manner, and reducing the expression of MuRF1.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/538 - Schizonepeta
• A61K 36/884 - Alismataceae (Water-plantain family)
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The present invention relates to an anti-coronavirus use of an antiviral composition containing a Ramulus-mori-derived compound as an active ingredient. Specifically, a Ramulus-mori-derived compound of the present invention exhibits an inhibitory effect on an infection caused by coronavirus such as SARS-coronavirus-2 (SARS-CoV-2), and thus relates to the development of an antiviral agent for preventing or treating viral diseases.

IPC Classes  ?

• A61K 36/605 - Morus (mulberry)
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61P 31/14 - Antivirals for RNA viruses
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms
• A23K 20/121 - Heterocyclic compounds containing oxygen or sulfur as hetero atom

Abstract

The present invention relates to an anti-coronavirus use of an antiviral composition containing a Geranium herb extract as an active ingredient. Specifically, the present invention relates to the development of an antiviral agent for preventing or treating viral diseases since a Geranium herb extract of the present invention exhibits an inhibitory effect on an infection caused by coronavirus such as SARS-coronavirus-2 (SARS-CoV-2).

IPC Classes  ?

• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61P 31/14 - Antivirals for RNA viruses
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

The present invention relates to a composition for preventing, alleviating, or treating allergic diseases, comprising an extract of Spatholobus suberectus as an active ingredient. The extract of Spatholobus suberectus of the present invention has an effect of reducing the secretion amount of chemokines (MDC and RANTES) and the formation amount of cytokines (IL-4), and thus may be advantageously utilized in functional health food or drugs for preventing, alleviating, or treating allergic diseases.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 37/08 - Antiallergic agents
• A61P 11/06 - Antiasthmatics
• A61P 27/14 - Decongestants or antiallergics

Abstract

Disclosed is a diagnostic model development technology for reproducing a cold sensation area based on abdominal palpation by a doctor of traditional medicine doctor, the technology procuring multiple pieces of data obtained by sketching a palpitated cold sensation area with an electronic pen on a notebook computer displaying a plurality of images captured in black and white, labeling the sketched position as ground truth to procure a semantic segmentation deep learning data set for detection in pixel units, using the data set for training that uses a deep neural network, and using a test set to verify the trained model, and deriving the final model.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/01 - Measuring temperature of body parts
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• G16H 20/90 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to alternative medicines, e.g. homeopathy or oriental medicines

Abstract

Disclosed is a technique related to a device assisting an abdominal examination conducted in oriental medicine. An abdominal examination index is determined on the basis of an oriental medicine abdominal examination model which has, as an input, a measurement value of a patient's abdomen. An oriental medicine abdominal examination device may, from characteristic variable values of three or more different domains, calculate, and output, probability values for a plurality of abdominal examination indexes, on the basis of the oriental medicine abdominal examination model. The abdominal examination indexes may be determined on the basis of the oriental medicine abdominal examination model which has, as inputs, measurement values obtained from a plurality of types of sensors in a plurality of regions of the patient's abdomen.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/01 - Measuring temperature of body parts
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• G16H 20/90 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to alternative medicines, e.g. homeopathy or oriental medicines
• A61B 7/04 - Electric stethoscopes
• G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising

Abstract

The present invention relates to a composition for the prevention, amelioration or treatment of poor ovarian responders caused by aging, comprising, as an active ingredient, a mixed medicinal herb extract consisting of Rehmannia glutinosa var. purpurea, Paeonia lactiflora, Cnidium officinale, and Angelica gigas, and statistically significant increases in the number of antral follicles and the number and quality of mature oocytes were confirmed in 40-week-old mice corresponding to humans of 40 years old or older, to which the mixed medicinal herb extract was orally administered. In women, the number of primordial follicles in the ovary continues to decrease with aging, and moreover, the number of antral follicles, which is the stage right before ovulation, decreases. As a result, the number of ovulating healthy mature oocytes (MII oocytes) decreases, thus gradually reducing the possibility of pregnancy. The mixed medicinal herb extract of the present invention can improve the number of antral follicles and the number and quality of mature oocytes, and thus has the effect of increasing the chance of getting pregnant in older women.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 5/20 - Removal of unwanted matter, e.g. deodorisation or detoxification
• A61K 36/804 - Rehmannia
• A61K 36/65 - Paeoniaceae (Peony family), e.g. Chinese peony
• A61K 36/234 - Cnidium (snowparsley)
• A61K 36/232 - Angelica
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Abstract

The present invention relates to a composition for promoting uric acid excretion, comprising an herbal complex extract as an active ingredient. The herbal complex extract not only reduces uric acid levels in the blood and increases uric acid levels in urine, but also has the effect of increasing fractional excretion of uric acid, the effect of reducing the expression of URAT1 and GLUT9, which are transporters associated with the reabsorption of uric acid, in the kidney which is a major organ for uric acid excretion, and the effect of inhibiting the reabsorption of uric acid mediated by URAT1, and thus may be usefully employed as a health functional food for promoting uric acid excretion, or as medicine for treating hyperuricemia caused by decreased uric acid excretion.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 19/00 - Products from fruits or vegetablesPreparation or treatment thereof
• A23L 5/20 - Removal of unwanted matter, e.g. deodorisation or detoxification
• A61K 36/896 - Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
• A61K 36/79 - Schisandraceae (Schisandra family)
• A61K 36/258 - Panax (ginseng)
• A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents

Abstract

The present invention relates to antiviral use against coronavirus, including an Epimedium koreanum extract or a fragment thereof and, more particularly, to: an antiviral pharmaceutical composition against coronavirus, including an Epimedium koreanum extract or a fraction thereof; a pharmaceutical composition for the prevention or treatment of coronavirus infection disease; a method for the prevention or treatment of coronavirus infection disease with the pharmaceutical composition; a health functional food composition for the prevention or treatment of coronavirus infection disease, including an Epimedium koreanum extract or a fragment thereof; and a feed composition for the prevention or treatment of coronavirus inflection disease, including an Epimedium koreanum extract or a fraction thereof. The Epimedium koreanum extract of the present invention exhibits an inhibitory effect on inflection by coronaviruses such as MERS-coronavirus, SARS-coronavirus, and SARS-coronavirus-2, and thus, can be utilized in the development of antiviral drugs for the prevention or treatment of the viral diseases.

IPC Classes  ?

• A61K 36/296 - Epimedium
• A61P 31/14 - Antivirals for RNA viruses
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

The present invention relates to the antiviral use against coronavirus, comprising a Gynostemma pentaphyllum extract or a fraction thereof and, more particularly, to: an antiviral pharmaceutical composition against coronavirus, comprising a Gynostemma pentaphyllum extract or a fraction thereof; a pharmaceutical composition for preventing or treating coronavirus infectious diseases; a method for preventing or treating coronavirus infectious diseases by means of the pharmaceutical composition; a functional health food composition for preventing or relieving coronavirus infectious diseases, comprising a Gynostemma pentaphyllum extract or a fraction thereof; and a feed composition for preventing or relieving coronavirus infectious diseases, comprising a Gynostemma pentaphyllum extract or a fraction thereof. The Gynostemma pentaphyllum extract of the present invention shows an inhibitory effect against an infection of coronavirus such as MERS-coronavirus, SARS-coronavirus and SARS-coronavirus-2, and thus can be used for developing an antiviral agent for preventing or treating the viral diseases.

IPC Classes  ?

• A61K 36/424 - Gynostemma
• A61P 31/14 - Antivirals for RNA viruses
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

The present invention relates to an antiviral use of a natural product mixed extract or a fraction thereof against coronaviruses and, more specifically, to an antiviral pharmaceutical composition against coronaviruses, a pharmaceutical composition for prevention or treatment of coronavirus infection diseases, each pharmaceutical composition comprising a natural product mixed extract or a fraction thereof, a method for prevention or treatment of coronavirus infection diseases by using the pharmaceutical composition, a health functional food composition comprising a natural product mixed extract or a fraction thereof for prevention or alleviation of coronavirus infection diseases, and a feed composition comprising a natural product mixed extract or a fraction thereof for prevention or alleviation of coronavirus infection diseases. The natural product mixed extract of the present invention exhibits the effect of inhibiting the infection of coronaviruses such as MERS coronavirus, SARS coronavirus, and SARS coronavirus 2 and as such, can be used for developing an antiviral agent for preventing or treatment of the viral diseases.

IPC Classes  ?

• A61K 36/23 - Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
• A61K 36/234 - Cnidium (snowparsley)
• A61K 36/232 - Angelica
• A61K 36/65 - Paeoniaceae (Peony family), e.g. Chinese peony
• A61K 36/63 - Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
• A61K 36/534 - Mentha (mint)
• A61K 36/17 - Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
• A61K 36/28 - Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
• A61K 36/70 - Polygonaceae (Buckwheat family), e.g. spineflower or dock
• A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof

Abstract

The present invention relates to an antiviral use against coronavirus, comprising a Hovenia dulcis Thunb extract or a fraction thereof and, more specifically, to an antiviral pharmaceutical composition against coronavirus, comprising a Hovenia dulcis Thunb extract or a fraction thereof, a pharmaceutical composition for prevention or treatment of coronavirus infectious disease, a method for preventing or treating coronavirus infectious disease by using the pharmaceutical composition, a health functional food for prevention or amelioration of coronavirus infectious disease, comprising a Hovenia dulcis Thunb extract or a fraction thereof, and a feed composition for prevention or amelioration of coronavirus infectious disease, comprising a Hovenia dulcis Thunb extract or a fraction thereof. The Hovenia dulcis Thunb extract of the present invention exhibits an effect of inhibiting infection by coronaviruses such as MERS-coronavirus, SARS-coronavirus and SARS-coronavirus-2, and thus can be used to develop an antiviral agent for preventing or treating the viral disease.

IPC Classes  ?

• A61K 36/72 - Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
• A61P 31/14 - Antivirals for RNA viruses
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

The present invention relates to a composition for preventing or treating a cognitive disorder, comprising an Iris lactea extract or a fraction thereof, and, particularly, to: a pharmaceutical composition for preventing or treating a cognitive disorder, comprising an Iris lactea extract or a fraction thereof as an active ingredient; a food composition; a feed composition; and a method for treating a cognitive disorder using the pharmaceutical composition. The Iris lactea extract of the present invention shows an excellent normalization effect and memory enhancement effect with respect to a damage to the brain such as basal forebrain, white matter, and hippocampus, and, thus, can be effectively used for treatment of a cognitive disorder related to memory disorders and cerebrovascular disorders induced by the damage, such as vascular dementia and cerebral infarction.

IPC Classes  ?

• A61K 36/88 - Liliopsida (monocotyledons)
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

A method for treating sleep disturbance according to an embodiment of the present disclosure includes administering to a subject in need thereof a composition including saponarin of Chemical Formula 1, a salt thereof acceptable for use in food, or a hydrate thereof as an effective component: In an animal model with lack of sleep caused by caffeine, saponarin of the present invention restores the travel distance, mobility time, mobility frequency, and immobility time to normal as well as increases the mRNA expression of neuropeptide Y, cholecystokinin, and GABA A α1 receptor, thereby alleviating sleep disturbance. Therefore, the saponarin of the present invention can be advantageously used as a raw material for a functional health food or a pharmaceutical product for preventing, alleviating, or treating sleep disturbance.

IPC Classes  ?

• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates

Abstract

The present invention relates to a composition for inhibiting anticancer-agent-induced ovotoxicity, containing a mixed extract of medicinal herbs as an active ingredient. Administration of a mixed extract of medicinal herbs, in combination with anticancer agent administration, has the effects of inhibiting a decrease in the number or quality of ova, caused by side effects of anticancer agents, increasing development capability of a blastocyst before implantation, and enhancing implantability in the body. Therefore, the mixed extract of medicinal herbs of the present invention can be effectively used as an anticancer adjuvant for inhibiting anticancer-agent-induced ovotoxicity.

IPC Classes  ?

• A61K 36/804 - Rehmannia
• A61K 36/65 - Paeoniaceae (Peony family), e.g. Chinese peony
• A61K 36/234 - Cnidium (snowparsley)
• A61K 36/232 - Angelica
• A61P 35/00 - Antineoplastic agents
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives

Abstract

The present invention relates to a composition comprising an Anethum graveolens extract as an active ingredient for prevention, alleviation, or treatment of bone diseases. The Anethum graveolens extract has the effect of inhibiting the differentiation of osteoclasts and increasing the bone density and bone volume of spongy bones in ovariectomized animal models without reducing the viability of osteoclast progenitor cells. Therefore, the Anethum graveolens extract of the present invention can be advantageously used as a health functional food or medicine for prevention, alleviation, or treatment of bone diseases.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/23 - Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
• A61P 19/00 - Drugs for skeletal disorders

Abstract

A method for treating sleep disturbance according to an embodiment of the present disclosure includes an extract of Fraxinus sp. plant as an effective component. As the extract of Fraxinus rhynchophylla of the present invention has an effect of ameliorating sleep disturbance by increasing the mRNA expression level of calretinin, neuropeptide Y, GAD65 and GAD67 in an animal model which has sleep disturbance caused by stress, it can be advantageously used as a raw material of a functional health food or a pharmaceutical product for preventing, ameliorating, or treating sleep disturbance.

IPC Classes  ?

• A61K 36/63 - Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
• A61P 25/20 - HypnoticsSedatives
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives

Abstract

The present invention relates to a composition for preventing, alleviating, or treating bone diseases, containing a Mentha arvensis extract as an active ingredient. The Mentha arvensis extract has the effects of inhibiting the differentiation of osteoclasts and promoting the differentiation of osteoblasts, increasing the survival rate of osteoclast precursor cells, and increasing the bone mineral density and bone volume of trabecular bone in an ovariectomized animal model. Therefore, the Mentha arvensis extract of the present invention can be effectively used as a health functional food or a medicine for preventing, alleviating, or treating bone diseases.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/534 - Mentha (mint)
• A61P 19/00 - Drugs for skeletal disorders
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

The present invention relates to a composition for preventing, alleviating, or treating bone diseases, containing an Euonymus sp. plant extract as an active ingredient, wherein the Euonymus sp. plant extract has the effects of inhibiting osteoclast differentiation and promoting osteoblast differentiation. Therefore, an Euonymus sp. plant extract according to the present invention can be effectively used as a health functional food or medicine for preventing, alleviating, or treating bone diseases.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/37 - Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
• A61P 19/00 - Drugs for skeletal disorders
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

gardenia fruit from which pigment is not removed, the composition can be very advantageously used for allergic skin diseases, in particular, atopic dermatitis.

IPC Classes  ?

• A61K 36/744 - Gardenia
• A23L 5/20 - Removal of unwanted matter, e.g. deodorisation or detoxification
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61P 17/04 - Antipruritics
• A61P 37/08 - Antiallergic agents
• B01D 11/02 - Solvent extraction of solids
• B01D 15/12 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the preparation of the feed

Abstract

The present invention relates to a screening composition, comprising a CoV RdRp expression vector and a bicistronic reporter vector, for a therapeutic agent for coronavirus infection, a screening kit, comprising the composition, for a therapeutic agent for coronavirus infection, and a method for screening a therapeutic agent for coronavirus infection by using the composition or kit. The screening composition for a therapeutic agent for coronavirus infection, provided by the present invention, can be used to screen candidate materials having direct influences on the activity of CoV RdRp, more quickly and easily, thus finding wide applications in the development of a therapeutic agent for coronavirus infection.

IPC Classes  ?

• C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to an alimentotherapy technique by which a therapeutic effect is obtained through food. A method for an alimentotherapy information system to manage alimentotherapy information comprises: receiving an input of ancient literature material including past alimentotherapy literature and culinary literature; extracting original information from the input ancient literature material, wherein the original information includes herbal medicine information for alimentotherapy and food information required for cooking; generating ingredient information, including site of activity, processing method, blending composition, medicinal properties and effectiveness, administration method, etc., from the extracted original information, and many-to-many matching foods to the medicines, wherein the original information is integrated on the basis of a single subject matter; and refining the alimentotherapy information of the integrated original information so as to conform to modern safety standards by referencing modern medical information, food ingredient compositions, and safety information.

IPC Classes  ?

• G16H 20/60 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
• G16H 70/60 - ICT specially adapted for the handling or processing of medical references relating to pathologies
• G16H 20/90 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to alternative medicines, e.g. homeopathy or oriental medicines
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
• G06F 40/205 - Parsing
• G06F 40/10 - Text processing
• G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring

Abstract

The present invention relates to a composition for relieving a hangover, containing Pediococcus inopinatus as an active ingredient. Specifically, Pediococcus inopinatus WiKim0108 not only has no cytotoxicity, but also reduces the content of ethanol and acetaldehyde in blood that has been increased by ingestion of alcohol, effectively increases ADH and ALDH activity in the blood, and has a gastrointestinal protective function. Thus, the composition of the present invention can be effectively used as a functional health food or medicine for hangover relief or alcoholic gastrointestinal diseases.

IPC Classes  ?

• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present invention relates to a composition for preventing, alleviating, or treating arteriosclerosis, containing Cannabis sativa L. stem extract as an active ingredient. It has been identified that a Cannabis sativa L. stem extract shows almost no cytotoxicity and reduces the amount of intracellular lipid and the expression of cholesterol biosynthesis pathway-related genes and increases the expression of genes for discharging cholesterol. Therefore, it is expected that a Cannabis sativa L. stem extract, which is an active ingredient of the present invention, is effectively usable as a composition for preventing, alleviating, or treating arteriosclerosis.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A23L 19/00 - Products from fruits or vegetablesPreparation or treatment thereof
• A23L 5/20 - Removal of unwanted matter, e.g. deodorisation or detoxification

Abstract

The present invention relates to a composition for preventing, alleviating or treating androgen-dependent diseases, containing a bamboo leaf extract as an active ingredient. Compared to other types of bamboo extracts, a bamboo leaf extract of the present invention significantly reduces the expression level of a SRD5A2 gene that codes for 5α-reductase, is hardly cytotoxic, reduces the weight of the prostate, reduces the proliferation of prostate tissue epidermal cells, and reduces the amounts of serum testosterone, dihydrotestosterone, PSA and SRD5A2, thereby being effectively usable for androgen-dependent diseases.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/899 - Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
• A61P 5/24 - Drugs for disorders of the endocrine system of the sex hormones
• A61K 8/9794 - Liliopsida [monocotyledons]
• A61Q 7/00 - Preparations for affecting hair growth
• A23L 19/00 - Products from fruits or vegetablesPreparation or treatment thereof

Abstract

The present invention relates to a composition for preventing, ameliorating or treating an androgen-dependent disorder comprising Phyllostachys pubescens extract as an effective component. It was found that, compared to the extracts of other types of bamboo, the Phyllostachys pubescens extract of the present invention can significantly reduce the expression amount of the SRD5A2 gene which encodes 5?-reductase while hardly showing any cytotoxicity. The composition of the present invention was found to have effects that can reduce the prostate weight, reduce the proliferation of epithelial cells in prostate tissues, and also can reduce the content of testosterone, dihydrotestosterone, PSA, and SRD5A2 in blood serum. Thus, the composition of the present invention can be advantageously used for an androgen-dependent disorder.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 8/9794 - Liliopsida [monocotyledons]
• A61K 36/899 - Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
• A61P 5/24 - Drugs for disorders of the endocrine system of the sex hormones

Abstract

The present invention relates to: a vaccine immune adjuvant composition containing bavachin as an active ingredient, the composition enabling antibody titer to be improved when administered with an antigen and cellular immunity and humoral immunity to be enhanced; a vaccine formulation containing bavachin and an antigen; a method for promoting immune responses, comprising a step of administering an individual with both the vaccine immune adjuvant composition and a vaccine composition or before or after administration of the vaccine composition; and a vaccine adjuvant composition for promoting immune responses, containing bavachin. A vaccine immune adjuvant composition of the present invention contains bavachin isolated from a Psoraleae semen extract of which the safety is ensured, and thus is safe, and can enhance the titer of an antibody produced according to an antigen and both humoral immunity and cellular immunity, thereby being widely usable in the development of an effective vaccine formulation.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Hibiscus syriacus extract as an effective ingredient as an effective ingredient can be advantageously used as a functional health food composition or a pharmaceutical composition for preventing, ameliorating or treating sleeping disorders.

IPC Classes  ?

• A61K 36/185 - Magnoliopsida (dicotyledons)
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61P 25/20 - HypnoticsSedatives

Abstract

A Sikchijeho-tang composition of the present invention exhibits a blood circulation-enhancing effect as high as or higher than that of Gagamjeho-tang comprising a smoky Prunus mume fruit, a Amomum villosum LOUR. fruit, an Amomum tsao-ko fruit, and a Pterocarpus santalinus stem and is free of an Amomum tsao-ko fruit and a Pterocarpus santalinus stem, which are both prohibited from being used as foods, and employs either Agastache rugosa or Agastache rugosa and Citrus maxima, whereby the composition can be industrially prepared into foods, beverages, and medicinal products.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 2/04 - Extraction of juices
• A23L 2/08 - Concentrating or drying of juices
• A23L 21/25 - HoneyHoney substitutes
• A23L 19/00 - Products from fruits or vegetablesPreparation or treatment thereof
• A61K 36/736 - Prunus, e.g. plum, cherry, peach, apricot or almond
• A61K 36/906 - Zingiberaceae (Ginger family)
• A61K 36/532 - Agastache, e.g. giant hyssop
• A61K 36/752 - Citrus, e.g. lime, orange or lemon
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors

Abstract

Disclosed are a method for assessing degenerative cognitive decline on the basis of eye movement and an apparatus for evaluating degenerative cognitive decline on basis of eye movement. According to one embodiment of the present invention, a method for evaluating degenerative cognitive decline on the basis of eye movement comprises the steps of: analyzing forward and reverse saccadic eye movements of eyeballs for tracking a moving target; measuring an error rate regarding a degree of deviation of the movement of the eyeballs from the movement path of the target through the analysis; measuring a response delay time required for the eyeballs to track the target in a predetermined interval in which the target moves through the analysis; and when any one of the error rate and the response delay time is greater than or equal to a predetermined threshold value, determining that a subject who recognizes an object through the eyeballs has cognitive decline.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
• A61B 3/11 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for measuring interpupillary distance or diameter of pupils

Abstract

The present invention relates to a composition for preventing or ameliorating Alzheimer's dementia, comprising a Tetragonia teragonioides extract as an active ingredient. By using this, accumulation of β-amyloids in the brain tissue is prevented, expression of brain-derived neurotrophic factor (BDNF) and ciliary neurotrophic factor (CNTF) genes is increased, and expression of Tau genes forming neurofibrillary tangles (MTF), known as a cause of Alzheimer's dementia, is reduced, thereby preventing, ameliorating or treating Alzheimer's dementia, specifically of β-amyloid accumulation type and Tau protein accumulation type.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to a composition, comprising a Salvia plebeia R. Br. extract as an active ingredient, for inhibiting tumor growth. A Salvia plebeia R. Br. extract was found to bind to PD-L1 present on cancer cell surfaces to block the interaction of cancer cells with PD-1 on the surface of immune T cells, thereby activating T cells to show a suppressive effect on tumor growth. When T cells were cocultured with colorectal cancer, breast cancer, or lung cancer cells, an effect of killing cancer cells was found to be improved in a Salvia plebeia R. Br. extract-treated group.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/537 - Salvia (sage)
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• A61P 31/04 - Antibacterial agents
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Provided is a composition for preventing or treating obesity including a mixed extract of Cinnamomi twigs, and more particularly, a pharmaceutical composition for preventing or treating obesity including a mixed extract of Cinnamomi twigs and Moutan root bark, a health functional food composition of feed composition for preventing or alleviating obesity including the composition, and a method of preventing or treating obesity including administering the pharmaceutical composition to an individual having obesity or a risk of developing obesity. The mixed extract of Cinnamomi twigs and Moutan root bark may inhibit fat absorption in the intestinal tract and increases in body weight causing obesity by single-dose administration, reduce lipid content in the blood, decrease weight and size of adipocytes, effectively inhibit accumulation of fat in liver tissue, and inhibit diarrhea, a serious side effect of Xenical™, by long-term administration.

IPC Classes  ?

• A61K 36/65 - Paeoniaceae (Peony family), e.g. Chinese peony
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61K 36/54 - Lauraceae (Laurel family), e.g. cinnamon or sassafras

Abstract

The present invention relates to a three-dimensional face image capturing method and comprises the steps of: capturing a face region of a user in a direction from a right chin to a left forehead; capturing the face region in a direction from a left forehead to a left chin; capturing the face region in a direction from a left chin to a right forehead; and capturing the face region in a direction from a right forehead to a center of face.

IPC Classes  ?

• H04N 13/221 - Image signal generators using stereoscopic image cameras using a single 2D image sensor using the relative movement between cameras and objects
• G06T 7/579 - Depth or shape recovery from multiple images from motion

Abstract

The present invention relates to a pharmaceutical composition for use in the prevention or treatment of a degenerative brain disease or a composition for use in neuroprotection, comprising a Periostracum Cicadae extract. In addition, the present invention relates to a method for preventing or treating a degenerative brain disease, comprising the step of administering a Periostracum Cicadae extract to a patient with the degenerative brain disease. The Periostracum Cicadae extract of the present invention amplifies neurotrophic factors or dopamine by increasing the activity of Nurr1 proteome, and has a neuroprotection effect by inhibiting neuronal cell death or nerve inflammation, thereby ameliorating behavior disorders caused by a degenerative brain disease such as Parkinson's disease, and furthermore can be expected to have the effect of ameliorating lowering of concentration, ADHD, schizophrenia, depression, or manic depression resulting from a dopamine decrease.

IPC Classes  ?

• A61K 35/64 - Insects, e.g. bees, wasps or fleas
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives